These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 20085390)

  • 1. Access with evidence development schemes: a framework for description and evaluation.
    McCabe CJ; Stafinski T; Edlin R; Menon D;
    Pharmacoeconomics; 2010; 28(2):143-52. PubMed ID: 20085390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Access with evidence development in the UK: past experience, current initiatives and future potential.
    Briggs A; Ritchie K; Fenwick E; Chalkidou K; Littlejohns P
    Pharmacoeconomics; 2010; 28(2):163-70. PubMed ID: 20085392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.
    Stafinski T; McCabe CJ; Menon D
    Pharmacoeconomics; 2010; 28(2):113-42. PubMed ID: 20085389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions.
    Walker S; Sculpher M; Claxton K; Palmer S
    Value Health; 2012 May; 15(3):570-9. PubMed ID: 22583469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the value of implementing reimbursement decisions: What can payers and manufacturers learn from economics?
    Dixon S
    Healthc Manage Forum; 2019 Nov; 32(6):303-306. PubMed ID: 31248283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pricing and reimbursement frameworks in Central Eastern Europe: a decision tool to support choices.
    Kolasa K; Kalo Z; Hornby E
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):145-55. PubMed ID: 24964864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving Access to High-Cost Technologies in the Asia Region.
    Mundy L; Trowman R; Kearney B
    Int J Technol Assess Health Care; 2019 Jan; 35(3):168-175. PubMed ID: 31122302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uncertainty and Coverage With Evidence Development: Does Practice Meet Theory?
    Pouwels XGLV; Grutters JPC; Bindels J; Ramaekers BLT; Joore MA
    Value Health; 2019 Jul; 22(7):799-807. PubMed ID: 31277827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence-based decision making: when should we wait for more information?
    Chalkidou K; Lord J; Fischer A; Littlejohns P
    Health Aff (Millwood); 2008; 27(6):1642-53. PubMed ID: 18997223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Not Available].
    Adenot I; Camus D; Épis de Fleurian AA; Tassy D; ; Bourguignon S; Chabin N; Chambrin PY; Costagliola D; Huot L; Joly AS; Le Lous G; Martelli N; Orlikowski D; Petit V; Puc C; Roussel C; Wilquin-Bequet F
    Therapie; 2020; 75(1):71-83. PubMed ID: 32044105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the added value of health technologies: reconciling different perspectives.
    Drummond M; Tarricone R; Torbica A
    Value Health; 2013; 16(1 Suppl):S7-13. PubMed ID: 23317646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug reimbursement policies in Canada--need for improved access to critical therapies.
    LeLorier J; Bell A; Bougher DJ; Cox JL; Turpie AG
    Ann Pharmacother; 2008 Jun; 42(6):869-73. PubMed ID: 18477735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers.
    Carlson JJ; Sullivan SD; Garrison LP; Neumann PJ; Veenstra DL
    Health Policy; 2010 Aug; 96(3):179-90. PubMed ID: 20226559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Waiting for reimbursement of new medicines in Canada: it's time for a rethink.
    Skinner BJ
    Pharmacoeconomics; 2008; 26(8):629-32. PubMed ID: 18620457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Access with evidence development: the US experience.
    Mohr PE; Tunis SR
    Pharmacoeconomics; 2010; 28(2):153-62. PubMed ID: 20085391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Framework for describing and classifying decision-making systems using technology assessment to determine the reimbursement of health technologies (fourth hurdle systems).
    Hutton J; McGrath C; Frybourg JM; Tremblay M; Bramley-Harker E; Henshall C
    Int J Technol Assess Health Care; 2006; 22(1):10-8. PubMed ID: 16673675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Principles of design of access with evidence development approaches: a consensus statement from the Banff Summit.
    Menon D; McCabe CJ; Stafinski T; Edlin R;
    Pharmacoeconomics; 2010; 28(2):109-11. PubMed ID: 20085388
    [No Abstract]   [Full Text] [Related]  

  • 18. Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?
    Menon D; Clark D; Stafinski T
    Healthc Policy; 2015 Aug; 11(1):15-32. PubMed ID: 26571466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there an alternative to quality-adjusted life years for supporting healthcare decision making?
    Beresniak A; Dupont D
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):351-7. PubMed ID: 27139424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.
    MacLeod TE; Harris AH; Mahal A
    Patient; 2016 Jun; 9(3):201-22. PubMed ID: 26370257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.